MGMT and neuroendocrine neoplasm: Moreover, MGMT promoter hypermethylation may increase sensitivity to alkylating agents like Dacarbazine and Temozolomide, as observed in patients with glioblastoma, advanced melanoma, and neuroendocrine tumors [6,19,20].